An ongoing dialogue on HIV/AIDS, infectious diseases,
October 19th, 2011
Going, Going, Gone … HIV Treatment Failure Is Disappearing in People Who Take Their Meds
(Doesn’t take much.)
But over in Lancet Infectious Diseases — which has turned out to be a terrific journal, by the way — there’s a study reminding us that advances in HIV treatment in the late 2000s were truly spectacular.
The goal of the paper was to track the outcome of patients with “triple-class virologic failure” (TCVF) over the course of the last decade. Using data from 24 European cohorts, the investigators had access to over 90,000 patients, out of whom 2722 failed treatment with regimens that at some point contained the original three drug classes: NRTIs, PIs, and NNRTIs.
Rates of virologic suppression after TCVF steadily increased over the decade, from 19.5% in 2000 to 57.9% in 2009, and both AIDS complications and deaths declined. Significant predictors of virologic suppression by multivariable analysis included later calendar year, transmission category (MSM did the best), low viral load, and high CD4.
Those who had previously been able to achieve virologic suppression before TCVF were also more likely to be successfully treated — this clearly being a marker for good adherence. And although “past performance is no guarantee of future results,” it sure can be useful regardless. You have to assume that most of the 40% or so who did not achieve virologic suppression simply didn’t take their meds.
So what’s missing from their analysis?
Notably, because our objective was mainly descriptive, we did not attempt to further adjust for time-dependent variables such as access to new drugs …
In other words, the single most important factor for improved treatment outcomes in the 2000s — the introduction of darunavir, raltegravir, maraviroc, and etravirine — is left out.
(They also didn’t include data on resistance or adherence, but I suspect the former was tough to find, and the latter probably didn’t change all that much.)
So these results are either truly remarkable (if you follow HIV from a distance) or, if you are actively practicing HIV medicine day-to-day, are so obvious you can legitimately wonder why they did the study in the first place.
Both reactions are appropriate.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Elucidating Community-Acquired Pneumonia in Immunocompromised Individuals
- Subtyping Sepsis: Limited Common Ground?
- Ocular Syphilis Acquired from a Common Partner
- Concurrent Administration of RSV and Influenza Vaccines Appears Safe in Healthy Older Adults
- U.S. Recommendations for a Vaccine Against Tickborne Encephalitis Virus
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster